pipette
ENEnglish

RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

Jonne Terstappen, Emanuele Gustani‐Buss, Cassandra A. L. Simonich, Jason S. McLellan, Vicky Lynne Baillie, Jesse D. Bloom, Louis Bont, Mauricio T. Caballero, Klasina Chappin, Janissa J.A. van Duijn, Gavin Juviler, Robert Jan Lebbink, Isabelle C.E. van Lotringen, Joris J.T. Roggekamp, Anouk Versnel, Marco C. Viveen, Hanneke J.A.A. Van Zoggel, Eveline M. Delemarre, Aurelio Bonavia, Natalie I Mazur

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. In vitro generation of RSM01 resistant mutants has previously been unsuccessful. We systematically assessed the in vitro resistance barrier of RSM01 and the susceptibility of a panel of global contemporary strains to RSM01. Monoclonal antibody resistant mutants (MARMs) were generated by serially passaging triple plaque-purified RSV-A2 and RSV-B1 using HEp-2 cells under pressure from RSM01, nirsevimab, or palivizumab, followed by phenotypic and genotypic characterisation. Moderate resistance was defined as > 3-fold and high resistance as > 30-fold increase in IC 50 compared with parental virus. The susceptibility of contemporary global clinical strains to RSM01 was tested in a neutralisation assay. RSV-A and B strains developed high resistance to palivizumab and nirsevimab, while RSM01 pressure induced moderate resistance. No MARMs demonstrated a fitness advantage. RSM01 neutralised global contemporary strains. In conclusion, in vitro RSM01 resistance was infrequent and moderate and RSM01 had broad activity against circulating strains. The confirmation of the high barrier to resistance of RSM01 is encouraging and provides an alternative should resistance emerge with widespread use of current licensed anti-RSV mAbs.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 19 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-79029-z